Pomdoctor Limited (POM) Fair Value & Analysis
Healthcare · US · Market cap $7.2M
Pomdoctor Limited
POM · US
Risks
Fair value as of: Aug 21, 2026
From 1 valuation models · updated 2 days ago
Share price +18.6% over the past month.
Below-average quality, and screening another 81% overvalued on our models.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.2200). The favourable scenario is already priced in.
- Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.1200 to $0.2200) leaves room in how you read the outcome.
Price vs Fair Value (10 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 21, 2026.
How to read this chart
10‑month range $0.0750 – $6.09 · fair‑value band $0.1200 – $0.2200 · the $0.9500 price screens above the $0.1800 fair value. As of Aug 21, 2026.
Analysis
Pomdoctor Limited (POM) currently trades at $0.9500, while our model-based Fair Value estimate is $0.1800, implying the stock looks roughly 81.1% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Pomdoctor Limited generated revenue of $400M at a net margin of -53.2%. Revenue grew 17.2% year over year. Net debt stands at $443M. Fundamentals as of Aug 21, 2026
Our scenario range runs from $0.1200 (bear case) to $0.2200 (bull case); at $0.9500, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -81%, POM screens richer than that median.
Notify me when POM reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China.
Full company description
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company in involved in internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pomdoctor Limited reported revenue of $400M in FY2025 versus $215M in FY2021, a compound +16.7%/yr. Reported net income was −$213M in FY2025.
of which total revenue +16.2 pp · buybacks/dilution −17.7 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
POM screens 81% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 64 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | -14% |
| Raia Drogasil S.A RADL3 | R$18.00 | R$15.58 | -13% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | -37% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 726.02 MXN | +57% |
| MedPlus Health Services Limited MEDPLUS | ₹656.80 | ₹191.97 | -71% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | -21% |
| Yixintang Pharmaceutical Group 002727 | ¥11.61 | ¥9.45 | -19% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.31 | ¥10.05 | -38% |
Compare Pomdoctor Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Pomdoctor Limited (POM) overvalued or undervalued?
What is the fair value of POM?
What is the quality score of POM?
What is the revenue of Pomdoctor Limited (POM)?
What is the net profit margin of POM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pomdoctor Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.